GE HealthCare Secures FDA Clearance for Photonova Spectra CT System
GE HealthCare has received FDA 510(k) clearance for its next-generation photon-counting CT scanner, the Photonova Spectra.
GE HealthCare Technologies Inc. (NASDAQ:GEHC) has received 510(k) clearance from the U.S. Food and Drug Administration for its Photonova Spectra system. This new technology represents the company’s latest advancement in photon-counting computed tomography (CT) imaging. The regulatory approval marks a significant milestone for the firm, following the system’s initial introduction at the 2025 Radiological Society of North America meeting. Analysts currently identify GE HealthCare as a top-rated large-cap value stock, citing the company’s ongoing pipeline of medical innovation. The Photonova Spectra is designed to provide enhanced imaging capabilities, positioning the firm to further its reach in the diagnostic hardware market.